{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:09:39Z","timestamp":1793524179521,"version":"4.5.0"},"reference-count":65,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To summarize patients\u2019 preferences for disease-modifying antirheumatic drug (DMARD) therapy in rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We conducted a systematic review to identify English-language studies of adult patients with RA that measured patients\u2019 preferences for DMARD or health states and treatment outcomes relevant to DMARD decisions. Study quality was assessed using a published quality assessment tool. Data on the importance of treatment attributes and associations with patient characteristics were summarized across studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>From 7951 abstracts, we included 36 studies from a variety of countries. Most studies were in patients with established RA and were rated as medium- (n = 19) or high-quality (n = 12). The methods to elicit preferences varied, with the most common being discrete choice experiment (DCE; n = 13). Despite the heterogeneity of attributes in DCE studies, treatment benefits (disease improvement) were usually more important than both non-serious (6 of 8 studies) and serious adverse events (5 of 8), and route of administration (7 of 9). Among the non-DCE studies, some found that patients placed high importance on treatment benefits, while others (in patients with established RA) found that patients were quite risk averse. Subcutaneous therapy was often but not always preferred over intravenous therapy. Patient preferences were variable and commonly associated with the sociodemographic characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Overall, the results showed that many patients place a high value on treatment benefits over other treatment attributes, including serious or minor side effects, cost, or route of administration. The variability in patient preferences highlights the need to individualize treatment choices in RA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.181165","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T12:24:08Z","timestamp":1555331048000},"page":"176-187","source":"Crossref","is-referenced-by-count":58,"title":["Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review"],"prefix":"10.3899","volume":"47","author":[{"given":"Caylib","family":"Durand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysoon","family":"Eldoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-8008","authenticated-orcid":false,"given":"Deborah A.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-3462","authenticated-orcid":false,"given":"Nick","family":"Bansback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-3741","authenticated-orcid":false,"given":"Glen S.","family":"Hazlewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"2020020109251867000_47.2.176.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2077-6"},{"key":"2020020109251867000_47.2.176.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.02.003"},{"key":"2020020109251867000_47.2.176.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.03.013"},{"key":"2020020109251867000_47.2.176.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5050","article-title":"Eliciting public preferences for healthcare: a systematic review of techniques","volume":"5","author":"Ryan","year":"2001","journal-title":"Health Technol Assess"},{"key":"2020020109251867000_47.2.176.5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.rdc.2018.01.009","article-title":"Measuring patient preferences: an overview of methods with a focus on discrete choice experiments","volume":"44","author":"Hazlewood","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"2020020109251867000_47.2.176.6","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(89)90136-4"},{"key":"2020020109251867000_47.2.176.7","first-page":"213","article-title":"Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics","volume":"2","author":"Bridges","year":"2003","journal-title":"Appl Health Econ Health Policy"},{"key":"2020020109251867000_47.2.176.8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/ncprheum0672","article-title":"How can we improve adherence to therapy by patients with rheumatoid arthritis?","volume":"3","author":"van den Bemt","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2020020109251867000_47.2.176.9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/PPA.S5835","article-title":"Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy","volume":"3","author":"Barton","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"2020020109251867000_47.2.176.10","unstructured":"Medical Subject Headings (MeSH). US National Library of Medicine. (Internet. Accessed April 3, 2018.) Available from: https:\/\/meshb.nlm.nih.gov\/record\/ui?ui=D057240"},{"key":"2020020109251867000_47.2.176.11","doi-asserted-by":"crossref","unstructured":"Hazlewood GS Barnabe C Tomlinson G Marshall D Devoe DJ Bombardier C . Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev 2016:CD010227.","DOI":"10.1002\/14651858.CD010227.pub2"},{"key":"2020020109251867000_47.2.176.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2527"},{"key":"2020020109251867000_47.2.176.13","doi-asserted-by":"crossref","first-page":"e007848","DOI":"10.1136\/bmjopen-2015-007848","article-title":"What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders","volume":"5","author":"Eiring","year":"2015","journal-title":"BMJ Open"},{"key":"2020020109251867000_47.2.176.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew280"},{"key":"2020020109251867000_47.2.176.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068296"},{"key":"2020020109251867000_47.2.176.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.24338"},{"key":"2020020109251867000_47.2.176.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019422"},{"key":"2020020109251867000_47.2.176.18","first-page":"2326","article-title":"Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis","volume":"32","author":"Chiou","year":"2005","journal-title":"J Rheumatol"},{"key":"2020020109251867000_47.2.176.19","first-page":"240","article-title":"Corticosteroids in patients with rheumatoid arthritis: utility measurements for evaluating risks and benefits","volume":"61","author":"Ferraz","year":"1994","journal-title":"Rev Rhum Engl Fr"},{"key":"2020020109251867000_47.2.176.20","first-page":"648","article-title":"Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses","volume":"28","author":"Suarez-Almazor","year":"2001","journal-title":"J Rheumatol"},{"key":"2020020109251867000_47.2.176.21","first-page":"255","article-title":"[Estimation of benefits and risks of the treatment of rheumatoid polyarthritis with glucocorticoids using the health-related quality of life measurements]","volume":"61","author":"Ferraz","year":"1994","journal-title":"Rev Rhum Ed Fr"},{"key":"2020020109251867000_47.2.176.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(96)00271-7"},{"key":"2020020109251867000_47.2.176.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.7.791"},{"key":"2020020109251867000_47.2.176.24","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300016160"},{"key":"2020020109251867000_47.2.176.25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/03009742.2011.566435","article-title":"How much is a reduction in morning stiffness worth to patients with rheumatoid arthritis?","volume":"125","author":"Tuominen","year":"2011","journal-title":"Scand J Rheumatol Suppl"},{"key":"2020020109251867000_47.2.176.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.3.253"},{"key":"2020020109251867000_47.2.176.27","first-page":"443","article-title":"Risk communication in rheumatoid arthritis","volume":"30","author":"Fraenkel","year":"2003","journal-title":"J Rheumatol"},{"key":"2020020109251867000_47.2.176.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.4.459"},{"key":"2020020109251867000_47.2.176.29","doi-asserted-by":"publisher","DOI":"10.1136\/jech.44.3.249"},{"key":"2020020109251867000_47.2.176.30","first-page":"1079","article-title":"Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making","volume":"10","author":"Bolge","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2020020109251867000_47.2.176.31","doi-asserted-by":"crossref","first-page":"e0149781","DOI":"10.1371\/journal.pone.0149781","article-title":"Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerability","volume":"11","author":"Navarro-Millan","year":"2016","journal-title":"PLoS One"},{"key":"2020020109251867000_47.2.176.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep354"},{"key":"2020020109251867000_47.2.176.33","first-page":"192","article-title":"Patients- and physicians- priorities for improvement. The case of rheumatic diseases","volume":"35","author":"da Silva","year":"2010","journal-title":"Acta Reumatol Port"},{"key":"2020020109251867000_47.2.176.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.10515"},{"key":"2020020109251867000_47.2.176.35","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20151"},{"key":"2020020109251867000_47.2.176.36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes196"},{"key":"2020020109251867000_47.2.176.37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/acr.22758","article-title":"When patients write the guidelines: patient panel recommendations for the treatment of rheumatoid arthritis","volume":"68","author":"Fraenkel","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2020020109251867000_47.2.176.38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40259-017-0244-3","article-title":"Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists","volume":"31","author":"van Overbeeke","year":"2017","journal-title":"BioDrugs"},{"key":"2020020109251867000_47.2.176.39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1524-4733.2008.00402.x","article-title":"Reliability of the discrete choice experiment at the input and output level in patients with rheumatoid arthritis","volume":"12","author":"Skjoldborg","year":"2009","journal-title":"Value Health"},{"key":"2020020109251867000_47.2.176.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.11.007"},{"key":"2020020109251867000_47.2.176.41","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X14532531"},{"key":"2020020109251867000_47.2.176.42","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31818af829"},{"key":"2020020109251867000_47.2.176.43","first-page":"CD001431","article-title":"Decision aids for people facing health treatment or screening decisions","volume":"1","author":"Stacey","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2020020109251867000_47.2.176.44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/PPA.S133222","article-title":"Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs","volume":"11","author":"Lofland","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"2020020109251867000_47.2.176.45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110207"},{"key":"2020020109251867000_47.2.176.46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020020109251867000_47.2.176.47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2020020109251867000_47.2.176.48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7417.745"},{"key":"2020020109251867000_47.2.176.49","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh116"},{"key":"2020020109251867000_47.2.176.50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12955-017-0698-5","article-title":"Development and use of a content search strategy for retrieving studies on patients\u2019 views and preferences","volume":"15","author":"Selva","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"2020020109251867000_47.2.176.51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jclinepi.2017.04.019","article-title":"Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences\u2019 studies","volume":"85","author":"Yepes-Nunez","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2020020109251867000_47.2.176.52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212407"},{"key":"2020020109251867000_47.2.176.53","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00296-017-3760-z","article-title":"Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective","volume":"37","author":"Husni","year":"2017","journal-title":"Rheumatol Int"},{"key":"2020020109251867000_47.2.176.54","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/PPA.S117774","article-title":"Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach","volume":"10","author":"Alten","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2020020109251867000_47.2.176.55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2017.10.003","article-title":"A Bayesian model that jointly considers comparative effectiveness research and patients\u2019 preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations","volume":"93","author":"Hazlewood","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2020020109251867000_47.2.176.56","first-page":"84","article-title":"Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis","volume":"9","author":"Louder","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2020020109251867000_47.2.176.57","first-page":"1101","article-title":"Patients\u2019 and rheumatologists\u2019 preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain","volume":"10","author":"Nolla","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2020020109251867000_47.2.176.58","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22265"},{"key":"2020020109251867000_47.2.176.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2009.04.004"},{"key":"2020020109251867000_47.2.176.60","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s10067-017-3731-5","article-title":"Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities","volume":"36","author":"Bacalao","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2020020109251867000_47.2.176.61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209835"},{"key":"2020020109251867000_47.2.176.62","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10067-017-3587-8","article-title":"Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study","volume":"36","author":"Desplats","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2020020109251867000_47.2.176.63","first-page":"93","article-title":"Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis","volume":"8","author":"Huynh","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"2020020109251867000_47.2.176.64","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0272989X17696995","article-title":"Comparison of the effects of a pharmaceutical industry decision guide and decision aids on patient choice to intensify therapy in rheumatoid arthritis","volume":"37","author":"Martin","year":"2017","journal-title":"Med Decis Making"},{"key":"2020020109251867000_47.2.176.65","doi-asserted-by":"publisher","DOI":"10.1002\/art.21405"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.181165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T12:27:36Z","timestamp":1580560056000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.181165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":65,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,1]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.3899\/jrheum.181165"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.181165","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]}}}